ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RMTI / news
NXTC (37) RNAZ (35) PMN (35) AARD (33) ⌘ Pro Terminal →

Why RMTI Stock dropped -2.26% Today — RQD Quant Desk Flash

$6.91 -2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.87

Rockwell Medical Inc. (RMTI) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $28.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RMTI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rockwell Medical Inc. (NASDAQ: RMTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $6.91 (-2.26% 1D, market cap $28.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RMTI ranks #953 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RMTI compare to NXTC and RNAZ in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RMTI carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 16.9%, and ROIC of -10.6%. By comparison, NXTC (NextCure Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $28.9M) and RNAZ (TransCode Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, RMTI leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RMTI?
▼

Per RMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041024), Rockwell Medical Inc. generated $69.3M in revenue (-31.8% YoY), -$5.3M in net income, and -$659.0K in free cash flow against $57.1M in total assets and $8.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.87 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (5)Whales (4)SEC (5)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.8% Base Target
$14 Bull$6 Base$5 Bear
📬 FREE RMTI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMTI)Realized 20D OHLCV Swing Band: ±12.1%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY RMTI SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (26% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 16.9% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$7.85-7.9% Next Q
Q2 (-2Q)
28
Grade E$7.23-5.1% Next Q
Q3 (-1Q)
26
Grade E$6.86+0.7% Next Q
Current
23
Grade E$6.91-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RMTI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RMTI currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.88) and Max Pain ($7.26) forces dealer call-delta covering toward $13.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMTI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RMTI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RMTI Stock dropped -2.26% Today — RQD Quant Desk Flash

Rockwell Medical Inc. (RMTI) dropped -2.26% to $6.91, trading at 25% of its 52-week range ($4.89 – $12.9). Stretched risk/reward at current multiples (-11% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 25% of its 52-week range ($4.89 – $12.9) with RSI-14 at 42.1 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.1% around $6.91 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 16.9% gross margin and $0 annual free cash flow.
Live RMTI Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RMTI)

  • ✓Walkthrough of RMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.36%🛡️ HOLDING TREND SUPPORT
2026-11-03O $7.31H $7.31L $6.91C $6.91VOL 39.5K
RES: $9.88SUP: $6.69SMA50: $7.88SMA200: $8.21
$11.02$9.36$7.70$6.04$4.37RES $9.88SUP $6.69$6.912026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RMTI Butterfly Map → + Track RMTI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -31.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RMTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RMTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMTI)

Health Care Rank #953 of 1015 ⚔️ NXTC vs RMTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMTI vs. NXTC, RNAZ, PMN, AARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rockwell Medical Inc. (RMTI) ranks #953 by composite RQD confidence (23/100, grade E) and #804 by equity capitalization ($28.5M). Within this direct 5-issuer industry benchmark cohort, RMTI leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with RMTI at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RMTI ACTIVE
Rockwell Medical Inc.
E 23/100 — 16.9% -10.6% -2.26% $28.5M Benchmark Subject
NXTC
NextCure Inc.
D- 37/100 — — -35.0% -9.75% $28.9M /nxtc-vs-rmti →
RNAZ
TransCode Therapeutics Inc.
D- 35/100 — — -35.0% 0.00% $27.6M /rnaz-vs-rmti →
PMN
ProMIS Neurosciences Inc. (ON)
D- 35/100 — — -35.0% -9.37% $29.7M /pmn-vs-rmti →
AARD
Aardvark Therapeutics Inc.
E 33/100 — — -35.0% -11.76% $29.8M /aard-vs-rmti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041024 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rockwell Medical Inc. (RMTI) reported GAAP revenue of $69.3M (-31.8% vs. FY2024 revenue of $101.5M , and +270.8% cumulative change since FY2023) , GAAP net income of -$5.3M, operating cash flow of -$659.0K, and free cash flow of -$659.0K (-115.7% YoY). On the balance sheet, RMTI closed FY2025 with $57.1M in total assets against $8.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $69.3M -$5.3M -$659.0K -$659.0K $57.1M $8.8M
FY2024 (FY) 2024-12-31 $101.5M -$480.0K $4.2M $4.2M $59.2M $8.5M
FY2023 (FY) 2023-12-31 $18.7M -$8.4M -$9.4M -$9.4M — —

3. RMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rockwell Medical Inc. (NASDAQ: RMTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $6.91 (-2.26% 1D, market cap $28.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RMTI ranks #953 in composite RQD confidence.

How does RMTI compare to NXTC and RNAZ in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RMTI carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 16.9%, and ROIC of -10.6%. By comparison, NXTC (NextCure Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $28.9M) and RNAZ (TransCode Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, RMTI leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RMTI?

Per RMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041024), Rockwell Medical Inc. generated $69.3M in revenue (-31.8% YoY), -$5.3M in net income, and -$659.0K in free cash flow against $57.1M in total assets and $8.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RMTI trading relative to its 50-day, 200-day, and 52-week technical levels?

RMTI last traded at $6.91 (-2.26% on volume of 10,657 shares), positioning the stock -12.31% below its 50-day simple moving average ($7.88) and -15.83% below its 200-day simple moving average ($8.21). Across its 52-week range of $4.89 to $12.90, RMTI sits at the 25.2% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($6.07 to $7.75).

Direct Sub-Reports: RMTI RQD Cockpit RMTI 12M Forecast RMTI Earnings & Move RMTI Dividends & DRIP RMTI Insiders & 13F RMTI Whale Options RMTI Profit Sankey RMTI News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

RMTI — Rockwell Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rockwell Medical Inc. (RMTI) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $6.91 (-2.26% 1D, market capitalization $28.5M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -10.6%, gross margin of 16.9%, operating margin of -6.8%, and free cash flow yield of -2.24%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 0.24x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rockwell Medical Inc. (RMTI) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $0.0B, which differs from the $29.5M in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rockwell Medical Inc. (RMTI) reported $69.3M in annual revenue (up from $101.5M in FY2024, -31.8% YoY) and -$5.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.7M revenue, -$8.4M net income) through FY2025, RMTI scaled operating cash flow to -$659.0K and free cash flow to -$659.0K, backed by $57.1M in total assets against $8.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.24% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $4.89 – $12.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -6.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks.

  • Key Question #1: Can RMTI sustain or expand its -6.8% operating margin and -10.6% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $69.3M and free cash flow of -$659.0K, how will capital allocation balance growth reinvestment against $8.8M in total debt?
  • Key Question #3: How sensitive is RMTI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RMTI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rockwell Medical Inc. (RMTI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RMTI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RMTI Bull vs. Bear Conversation Board — What's Your Call at $6.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RMTI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RMTI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $8.48 (+19.9%)
📌 Pinned Debate

Cash of $10.7M and a Debt/Equity of 0.24 give the company a non-trivial balance sheet cushion against its current losses.

Long RMTI at $7.07 targeting $8.48. Cash of $10.7M and a Debt/Equity of 0.24 give the company a non-trivial balance sheet cushion against its current losses.. Institutional whale score is 4/20 and the risk/reward vs. the $4.89 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 4/20 institutional whale-flow stock at $7.07 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $5.94 (-16.0%)
Spot @ $7.07

ROIC of -10.6%, FCF yield of -2.24%, and revenue falling from $101.5M to $69.3M point to a deteriorating cash engine with a weak RQD ra

I respect the product at Rockwell Medical Inc., but the stock at $7.07 is a different story. ROIC of -10.6%, FCF yield of -2.24%, and revenue falling from $101.5M to $69.3M point to a deteriorating cash engine with a weak RQD rating.. FCF yield is -2.24% and RQD sits at 23/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE